Tg Therapeutics (TGTX) Operating Income (2011 - 2026)

Tg Therapeutics' Operating Income history runs 16 years deep, the most recent figure standing at $34.8 million for Q1 2026.

• In Q1 2026, Operating Income rose 303.56% year-over-year to $34.8 million; the TTM figure through Mar 2026 stood at $149.5 million (up 149.91% YoY), while the FY2025 annual figure was $123.3 million, up 194.13% from the prior year.
• Operating Income for Q1 2026 stood at $34.8 million, down from $50.5 million in the prior quarter.
• The five-year high for Operating Income was $114.8 million in Q3 2023, with the low at -$77.5 million in Q4 2022.
• The 5-year median for Operating Income is $8.6 million (2025), against an average of $139176.5.
• The sharpest annual moves came in 2023 and 2024: Operating Income jumped 428.3% in 2023, then slumped 89.17% in 2024.
• Tg Therapeutics' Operating Income stood at -$77.5 million in 2022, then jumped by 83.9% to -$12.5 million in 2023, then soared by 339.88% to $29.9 million in 2024, then surged by 68.6% to $50.5 million in 2025, then tumbled by 31.09% to $34.8 million in 2026.
• Business Quant data shows TGTX's Operating Income at $34.8 million in Q1 2026, $50.5 million in Q4 2025, and $29.4 million in Q3 2025.